Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 7;9(4):67.
doi: 10.3390/ijns9040067.

Newborn Genetic Screening-Still a Role for Sanger Sequencing in the Era of NGS

Silje Hogner  1 , Emma Lundman  1 , Janne Strand  1 , Mari Eknes Ytre-Arne  1 , Trine Tangeraas  1 , Asbjørg Stray-Pedersen  1
Affiliations

Newborn Genetic Screening-Still a Role for Sanger Sequencing in the Era of NGS

Silje Hogner et al. Int J Neonatal Screen. .

Abstract

In the Norwegian newborn screening (NBS) program, genetic testing has been implemented as a second or third tier method for the majority of NBS disorders, significantly increasing positive predictive value (PPV). DNA is extracted from dried blood spot (DBS) filter cards. For monogenic disorders caused by variants in one single gene or a few genes only, Sanger sequencing has been shown to be the most time- and cost-efficient method to use. Here, we present the Sanger sequencing method, including primer sequences and the genetic test algorithms, currently used in the Norwegian newborn screening program.

Keywords: Sanger sequencing; dried bloodspots; extraction; newborn screening.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Tangeraas T., Sæves I., Klingenberg C., Jørgensen J., Kristensen E., Gunnarsdottir G., Hansen E.V., Strand J., Lundman E., Ferdinandusse S., et al. Performance of Expanded Newborn Screening in Norway Supported by Post-Analytical Bioinformatics Tools and Rapid Second-Tier DNA Analyses. Int. J. Neonatal Screen. 2020;6:51. doi: 10.3390/ijns6030051. - DOI - PMC - PubMed
    1. Lundman E., Gaup H.J., Bakkeheim E., Olafsdottir E.J., Rootwelt T., Storrøsten O.T., Pettersen R.D. Implementation of newborn screening for cystic fibrosis in Norway. Results from the first three years. J. Cyst. Fibros. 2016;15:318–324. doi: 10.1016/j.jcf.2015.12.017. - DOI - PubMed
    1. Strand J., Gul K.A., Erichsen H.C., Lundman E., Berge M.C., Trømborg A.K., Sørgjerd L.K., Ytre-Arne M., Hogner S., Halsne R., et al. Second-Tier Next Generation Sequencing Integrated in Nationwide Newborn Screening Provides Rapid Molecular Diagnostics of Severe Combined Immunodeficiency. Front. Immunol. 2020;11:1417. doi: 10.3389/fimmu.2020.01417. - DOI - PMC - PubMed
    1. Helse og Omsorgsdepartementet Forskrift om Genetisk Masseundersøkelse av Nyfødte. [(accessed on 27 March 2022)]. Available online: https://lovdata.no/dokument/SF/forskrift/2007-06-29-742.
    1. Skov M., Bækvad-Hansen M., Hougaard D.M., Skogstrand K., Lund A.M., Pressler T., Olesen H.V., Duno M. Cystic fibrosis newborn screening in Denmark: Experience from the first 2 years. Pediatr. Pulmonol. 2020;55:549–555. doi: 10.1002/ppul.24564. - DOI - PubMed